News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Can-Fite BioPharma's Drug CF102 Significantly Decreased Viral Load of HCV in a Patient with Liver Cancer


6/1/2010 11:19:47 AM

PETAH-TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, reported today that a significant decrease in HCV viral load was noted in a patient with liver cancer treated daily, orally with CF102, within the framework of a Phase I/II clinical study in liver cancer (hepatocellular carcinoma, HCC) patients.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES